EUVIMEDSkopri EUVIMED
CrossrefKarta ta’ informazzjoni

The evolution of tyrosine‐kinase‐targeted cancer therapies

Mike Leahy

Future Prescriber · 2006

DOI: 10.1002/fps.14 ↗
AstrattDettalji biblijografiċi

Astratt

Abstract It is now over 50 years since systemic agents were first used to treat malignant disease. Initial results were positive, with cytotoxic chemotherapy achieving success in haematological malignancies, but these successes have not been reproduced for the majority of adult solid tumours, principally because the approach does not target tumour cells sufficiently and exclusively. Copyright © 2006 John Wiley & Sons, Ltd.

Għarfien li jaqbel max-xogħol tiegħek.

Minn bidu b’xejn u riċerka personali tal-letteratura sal-Research Suite sħiħa.

Ara t-tariffi →

Il-full texts kollha tal-pubblikaturi huma inklużi?

Le. Ir-referenzi biblijografiċi, l-astratti u t-testi sħaħ huma kontenuti differenti. Jekk test sħiħ huwiex disponibbli jiddependi mis-sors, Open Access u l-liċenzji eżistenti tiegħek. Pjan ta’ EUVIMED ma jissostitwix drittijiet addizzjonali tal-pubblikaturi.

Ara t-tariffi →